Novartis has raised its forecast for revenue growth in 2023 against a backdrop of double-digit sales increases for key cardiovascular, oncology and multiple sclerosis medicines. Group sales are now expected to grow by a mid-single digit figure, a mark-up from the previously forecast low-to-mid single digit increase. The Switzerland-based company also expects to complete the spin-out of Sandoz, its generics and biosimilar medicines business, before the end of the year.
